From bloodjournal.hematologylibrary.org by guest on July 19, 2013. For personal use only.

2010 115: 2569-2577 Prepublished online January 28, 2010; doi:10.1182/blood-2009-09-199182

Structure and function of factor XI

Jonas Emsley, Paul A. McEwan and David Gailani

Updated information and services can be found at: http://bloodjournal.hematologylibrary.org/content/115/13/2569.full.html Articles on similar topics can be found in the following Blood collections Free Research Articles (1802 articles) Review Articles (455 articles) Thrombosis and Hemostasis (591 articles) Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.

From bloodjournal.hematologylibrary.org by guest on July 19, 2013. For personal use only.

Review article

Structure and function of factor XI

Jonas Emsley,1 Paul A. McEwan,1 and David Gailani2
1School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, United Kingdom; and 2Departments of Pathology and Medicine, Vanderbilt University, Nashville, TN

Factor XI (FXI) is the zymogen of an enzyme (FXIa) that contributes to hemostasis by activating factor IX. Although bleeding associated with FXI deciency is relatively mild, there has been resurgence of interest in FXI because of studies indicating it makes contributions to thrombosis and other processes associated with dysregulated coagulation. FXI is an unusual dimeric protease, with structural features that distinguish it from vitamin Kdependent coagulation pro-

teases. The recent availability of crystal structures for zymogen FXI and the FXIa catalytic domain have enhanced our understanding of structure-function relationships for this molecule. FXI contains 4 apple domains that form a disk structure with extensive interfaces at the base of the catalytic domain. The characterization of the apple disk structure, and its relationship to the catalytic domain, have provided new insight into the mechanism of FXI activation, the

interaction of FXIa with the substrate factor IX, and the binding of FXI to platelets. Analyses of missense mutations associated with FXI deciency have provided additional clues to localization of ligand-binding sites on the protein surface. Together, these data will facilitate efforts to understand the physiology and pathology of this unusual protease, and development of therapeutics to treat thrombotic disorders. (Blood. 2010; 115(13):2569-2577)

Introduction
Factor XI (FXI) is the zymogen of a blood coagulation protease, factor XIa (FXIa), that contributes to hemostasis through activation of factor IX (FIX; Figure 1).1-3 The protein is a 160-kDa disulde-linked dimer of identical 607 amino acid subunits, each containing 4 90- or 91-amino acid repeats called apple domains (A1 to A4 from the N-terminus) and a C-terminal trypsin-like catalytic domain.3-7 The structure is distinctly different from those of the well-characterized vitamin Kdependent coagulation proteases.1 FXI circulates in blood as a complex with high molecular weight kininogen (HK).8 Prekallikrein (PK), the zymogen of the protease -kallikrein, is a monomeric homolog of FXI with the same domain structure9,10 that also circulates in complex with HK.11 A recent analysis of vertebrate genomes conrmed that FXI and PK are products of a duplication event during mammalian evolution.12 The ancestral predecessor is also a protease with 4 apple domains, but its functional properties have not been studied.12 In the cascade/waterfall models of coagulation that are the basis for the activated partial thromboplastin time (aPTT) assay, FXI activation by FXIIa initiates brin formation (Figure 1).1 However, newer schemes do not assign FXI a role in early brin generation, based largely on the observation that FXI deciency causes relatively mild bleeding.1-3 FXIa is now postulated to be part of a feedback loop that sustains thrombin generation through FIX activation to consolidate coagulation (Figure 1).13-15 This appears to be particularly important in tissues with robust brinolytic activity, such as the oropharynx and urinary tract, which are common sites of bleeding in FXI-decient patients.2,16-23 Congenital FXI deciency is associated with a variable, mild to moderate bleeding disorder.2,16,17 Severe deciency ( 15% of normal plasma activity) is prevalent in people of Jewish ancestry.2,16,17,24 The carrier rate is approximately 5% in Ashkenazi Jews, with severe (homozygous) deciency found in 1 in 450 persons.16,24 Two mutations account for more than 90% of abnormal alleles in this population.24,25 The severe mutation Glu117Stop encodes a truncated protein,25 and homozygotes lack plasma FXI antigen. The more subtle missense mutation Phe283Leu causes a defect in FXI dimer formation.26-28 More than 180 other FXI gene mutations associated with FXI deciency have been reported (http://www.factorxi.org, http://www.isth.org),29 including more than 100 single amino acid (missense) substitutions. Congenital deciencies of vitamin Kdependent coagulation proteases are often associated with dysfunctional protein in plasma (crossreactive material positive [CRM] deciency).30 In contrast, most cases of FXI deciency are associated with low plasma levels of FXI protein (CRM deciency).31 There has been renewed interest in FXI as a result of populationbased studies and work with animal models strongly indicating that this protein makes important contributions to arterial32-36 and venous37 thrombosis, ischemia-reperfusion injury in the central nervous system,38 and the pathology of sepsis.39 The observation that deciency or inhibition of FXI interferes with platelet accumulation in growing thrombi33,35 has led to a reanalysis of the mechanisms involved in FXI activation and its interactions with platelets. In this review, we present a summary of recent structural data on FXI as it relates to current knowledge of protease function and to congenital FXI deciency.

FXI structure
Crystal structures are available for full-length zymogen FXI,7 and the isolated active protease domain of FXIa in complex with

Submitted September 6, 2009; accepted January 4, 2010. Prepublished online as Blood First Edition paper, January 28, 2010; DOI 10.1182/blood-2009-09199182.

The online version of this article contains a data supplement. 2010 by The American Society of Hematology

BLOOD, 1 APRIL 2010 VOLUME 115, NUMBER 13

2569

From bloodjournal.hematologylibrary.org by guest on July 19, 2013. For personal use only.
2570 EMSLEY et al BLOOD, 1 APRIL 2010 VOLUME 115, NUMBER 13

Figure 1. Plasma coagulation protease reactions. Scheme for the cascade/ waterfall model of thrombin generation triggered by activation of FXII. Conversion of FXI to FXIa is shown in red. A mechanism for initiation of coagulation by the FVIIa/TF complex through FX activation is also shown. Roman numerals indicate unactivated coagulation factors, and activated factors are indicated by a. Nonenzymatic cofactors are indicated by numerals in black ovals. The dotted line designated 1 indicates feedback activation of FXI by thrombin, whereas the dotted line indicated by 2 represents activation of FIX by FVIIa/TF.

disk-like platform around the base of the catalytic domain (Figure 2B).7,10 The disk has 2 sets of topologically equivalent interfaces. The side interfaces between A1 and A2 and between A3 and A4 are substantial, burying surface areas of 441 2 and 444 2, respectively. In comparison, the end interfaces between A1 and A4 (380 2) and between A2 and A3 (284 2) are smaller. The FXI subunit, therefore, is compact compared with the vitamin Kdependent proteases, whose elongated structures serve to position the catalytic domains above phospholipid membranes.1 Amino acid substitutions in the apple domains of FXI-decient patients are shown in Figure 2C. With few exceptions, these mutations involve residues that are conserved in FXI, PK, and their ancestral predecessor (supplemental Table 1, available on the Blood website; see the Supplemental Materials link at the top of the online article). Many involve buried residues (green in Figure 2C) that probably affect apple domain folding or disrupt formation of interdomain interfaces,29 which would explain why the majority of cases of FXI deciency are CRM.

natural and synthetic inhibitors.40-42 An NMR structure for the A4 domain dimer is also available.43 The apple domains of FXI and PK are members of the PAN (plasminogen, apple, nematode) module family, with homology to the N-terminal domains of hepatocyte growth factor and plasminogen.44 Each apple domain consists of 7 -strands that fold into a curved antiparallel sheet cradling an -helix (Figure 2A).7 Two disulde bonds lock the helix onto the central 4 and 5 strands, whereas a third connects the N- and C-termini of the domain. This core topology is equivalent to PAN domains from hepatocyte growth factor,44 leech antiplatelet protein,45 and microneme antigen EtMIC5.46 The 4-5 loop and 5-6 crossover loop generate a small pocket on the opposite side of the sheet from the -helix (Figure 2A). A remarkable feature of the FXI structure, which it probably shares with PK,10 is the intimate linkage of the apple domains into a

FXI dimer
The 2 A4 domains form a substantial interface (886 2) between the dimer subunits, with the -sheets packing against each other (Figure 2D).7 Cys321, which is located in a nger-like loop in A4, projects away from the body of the domain and forms the interchain disulde bond (Figure 2B,D). However, FXI with substitutions for Cys321 still form stable dimers.28,47-51 Leu284, Ile290, and Tyr329, which form the hydrophobic core of the A4 domain interface, are required for dimer formation,7,50,51 as are salt bridges between Lys331 of one subunit and Glu287 of the other.7,48 The Cys321-Cys321 interchain bond forms poorly in FXI with a single alanine substitution of Leu284, Ile290, or Tyr329,51 indicating that the interface between A4 -sheets forms before the disulde bond. A number of A4 domain mutations associated with
C321

A
1

B
2 7 6 4

Thrombin

pocket

HK
5 3

Heparin

FIX

GpIb

C D
C321-C321 Y329 I290

L284

Figure 2. Human FXI apple domains. Topology diagrams based on the FXI zymogen structure. For all diagrams, the rst, second, third, and fourth apple domains (A1, A2, A3, and A4) are shown in cyan, light blue, orange, and yellow, respectively. (A) The apple domain consists of a 7-stranded -sheet (blue) with a central -helix positioned on top (red). Disulde bonds are shown in orange. (B) Topology diagram showing the disk formed by the 4 apple domains, with the catalytic domain removed. Sites of residues implicated in ligand binding are red for thrombin, green for high-molecular-weight kininogen (HK), black for GPIb, blue for heparin, and orange for FIX. (C) Apple domain disk showing the positions of mutations identied in FXI-decient patients that involve buried residues (green) or surface exposed residues (red). Mutations Gly155Glu, Arg184Gly, and Ser248Asn (boxed) are examples of rare CRM mutations. (D) Two A4 domains forming the FXI dimer interface. The Cys321 interchain disulde bond is shown at the top in orange. Hydrophobic residues Leu284, Ile290, and Tyr329 are shown in black, and a salt bridge is formed between Lys331 (blue) and Glu287 (red).

From bloodjournal.hematologylibrary.org by guest on July 19, 2013. For personal use only.
BLOOD, 1 APRIL 2010 VOLUME 115, NUMBER 13 FACTOR XI STRUCTURE AND FUNCTION 2571

FXI deciency interfere, or are predicted to interfere, with dimerization. The best characterized are Phe283Leu,26-28 which causes a partial dimerization defect, and Gly350Glu,27 which prevents dimer formation. Riley et al showed that the Phe283Leu substitution causes increased dimer dissociation and stabilizes the monomer through altered side-chain packing that is unfavorable for dimer formation.28 The dimeric structure of FXI, unique among coagulation proteases, has implications for inheritance of FXI deciency.Although Glu117Stop and Phe283Leu are associated with a bleeding diathesis inherited as an autosomal recessive disorder (mutations in both alleles required for symptomatic deciency),2,27 signicant deciency can occur in heterozygotes for some types of mutations, as follows. An amino acid substitution could prevent protein secretion (CRM mutation) but not interfere with intracellular dimer formation. A FXI subunit containing such a mutation would exert a dominant-negative effect on normal FXI subunits by forming nonsecretable heterodimers with 1 normal and 1 abnormal subunit. The mutant subunit, in effect, traps wild-type subunits within the cell. This mechanism has been demonstrated in deciencies of multimeric proteins, such as von Willebrand factor52 and brinogen.53 The FXI missense mutations Ser225Phe, Cys398Tyr, Gly400Val, and Trp569Ser exhibit a dominant negative effect when coexpressed with wild-type FXI and are associated with FXI deciency that may be inherited in a dominant manner.27,54 It is probable that these mutations do not perturb apple domain disk structure signicantly, allowing dimerization to occur. In this regard, it is interesting to note that 3 of 4 mutations known to operate by a dominant negative mechanism involve residues in the catalytic domain. The structure of the FXI dimer is shown in Figure 3 with highlights on residues implicated in zymogen activation, substrate recognition, and receptor binding (also shown in Figure 2B). Many

of the complex protein-protein interactions involving FXI and FXIa are mediated by its apple domains. Binding sites for HK,10,55,56 thrombin,7,57 heparin,58-61 FIX,62,63 and platelet receptors, such as glycoprotein Ib (GPIb),64 will be discussed in the following sections.

FXI and PK binding to HK

HK is a 120-kDa multifunctional plasma protein with 6 domains, designated D1 to D6.65 Almost all FXI8 and 75% to 90% of PK11,66 circulate in a complex with HK. The D6 domain mediates binding to both proteins.65 The physiologic importance of the PK-HK interaction seems clear as cleavage of HK by -kallikrein (activated PK) liberates the vasoactive peptide bradykinin.65 The importance of the FXI-HK interaction is not as evident, as HK deciency is not associated with a bleeding disorder.30 In the presence of zinc ions, HK is required for optimal FXI binding to GP1b on activated platelets in suspension, enhancing the binding stoichiometry by approximately 2-fold.67-69 However, FXI binding to platelets assayed under ow (discussed in FXI interactions with platelet receptors) is not enhanced by HK.70 The sites on FXI and PK that bind HK are probably similar. Studies using FXI/PK chimeras, individual apple domains, and short peptide sequences derived from apple domains indicate the A2 domain is required for HK binding, with additional contributions from A1 and A4.55,56,71 Detailed mutagenesis to localize the binding site has not been performed; however, analysis of the natural FXI mutation Gly155Glu provides some information. Gly155Glu is a rare example of a mutation causing CRM FXI deciency.72,73 Gly155 is located at the center of a loop connecting the 5 and 6 strands of A2. The Gly155 main chain nitrogen forms a hydrogen bond with the carbonyl group of Thr152 in a type I -turn (Figure 4A). Gly155 points toward the center of a cavity in the apple domain disk and lies in a positively charged channel on the surface of A2 pointing away from the protease domain (Figure 4B).10 Recombinant FXI-Glu155 binds HK with approximately 10-fold lower afnity than wild-type FXI in a solid phase assay (D.G., unpublished observation, June 2008). The loop containing Gly155 forms hydrogen bonds with a second loop spanning residues 103 to 105 (Figure 4A) that contains the FXI mutation Gly104Asp and borders a pocket in the A2 domain at the end of the charged channel (Figure 4B). A Gly104Arg mutation in the PK A2 domain associated with CRM PK deciency also causes decreased HK binding.74

AS

AL

H2

C321 T

AL

H1 FIX

GpIb

HK

FXI zymogen activation

In vitro, known plasma activators of FXI include FXIIa,4 -thrombin,13,14,75 the prothrombin activation intermediate meizothrombin,76 and FXIa (autoactivation),13,15 all of which cleave FXI at the Arg369-Ile370 bond.5,6 Although FXIIa activates FXI in the cascade/waterfall model (Figure 1), the absence of a bleeding disorder in FXII-decient patients indicates that alternative mechanisms for FXI activation exist. This is demonstrated clearly by the work of Spronk et al using mice lacking FIX, FXI, or FXII on a background of low tissue factor (TF) expression.77 Low TF mice have a severe bleeding disorder but are viable.78 Superimposing FIX or FXI deciency on the low TF background results in death in utero from bleeding, implying FIX activation by FXIa is required for viability in the setting of a hemostatic system crippled by low

Figure 3. The structure of zymogen FXI. Topology diagram of dimeric FXI viewed from 2 perspectives rotated 90 degrees. The catalytic domain is in white. Sites of residues implicated in ligand binding are red for thrombin (T), green for HK, black for GPIb, blue for heparin sites (H1 and H2), and orange for FIX. Positions for the activation loop (AL) cleavage site (Arg360-Ile370) residue Ile370 and active site (AS) residues Ser557, Asp462, and His413 are shown in purple.

From bloodjournal.hematologylibrary.org by guest on July 19, 2013. For personal use only.
2572 EMSLEY et al BLOOD, 1 APRIL 2010 VOLUME 115, NUMBER 13

A
G155E

HK

G155

T152

G104D

G104

A2

Figure 4. FXI-binding site for HK. (A) The relative positions of Gly104 and Gly155 in the A2 domain are shown. Gly155 is involved in a tight -turn forming a hydrogen bond with Thr152. The compact hydrogen bond network extends through Thr152 and Thr158 to form contacts to the main chain through residues Lys103 and Ile105. Changes at Gly104 or Gly155 will probably disrupt this network. (B) Charged surface (blue represents positive; red, negative) representation of the underside of the FXI apple domain disk, showing positions of Gly104 and Gly155. These residues are required for proper formation of a charged channel that is a probable binding site for HK. The dotted line represents the predicted binding site of HK that terminates in a pocket at the base of the A2 domain.

study with similar FXI monomers gave somewhat contradictory results, with monomers proving more susceptible than dimers to spontaneous autoactivation by FXIa, but here experiments were conducted in conditioned media (unpuried system).51 The term FXIa describes the protease form of FXI that has been cleaved at the Arg369-Ile370 peptide bonds on both subunits of the dimer. Recently, FXI activation by thrombin or FXIIa was shown to proceed through an intermediate with 1 activated subunit, referred to as 1/2-FXIa.3,83 The intermediate can be observed on nonreducing sodium dodecyl sulfate-polyacryalmide gels because FXI, 1/2-FXIa, and FXIa migrate at slightly different rates (Figure 5). 1/2-FXIa can be detected in plasma induced to undergo contact activation.83 Given that conversion of FXI to fully activated FXIa is a slow process, 1/2-FXIa may be a major species of activated FXI. The functional properties of this protease are discussed further in Recognition and cleavage of FIX by FXIa.

FXIa protease domain structure and interactions with inhibitors

There are no structures available for full-length FXIa or 1/2-FXIa, but structures for isolated FXIa catalytic domain in complex with inhibitors have been reported.40-42 Comparison with the zymogen structure reveals conformational changes expected with activation of a serine protease, including a 12 movement of Ile370 (the N-terminus of the catalytic domain, Figure 6A) into the protease domain core. Trypsin-like proteases, including FXIa, cleave their substrates after basic amino acids (arginine in the case of FXIa) that are designated the P1 residue. The site on the protease that interacts with the substrate P1 residue is the S1 site. Changes in the catalytic domain that occur during FXI activation result in a salt bridge forming between the Ile370 N-terminal amine and the Asp554 side chain. This allows formation of the S1 site that will be occupied by the side chain of the P1 arginine from a substrate or inhibitor. A distinct conformational change is also observed in loops on the side of the catalytic domain opposite the active site cleft. This involves unraveling of a short -helix in the zymogen and a closing together of the loop containing Arg489 and a -hairpin to ll a pocket left empty by removal of the A3 domain, which forms an interface with the base of the catalytic domain in the zymogen (Figure 6A,C). The potential importance of this conformational

TF levels. Mice with deciency of FXII and low TF, on the other hand, are viable and phenotypically similar to low TF mice with normal FXII expression. Although these data conrm the impression that FXIIa is not required for FXI activation, they should not be interpreted as indicating that FXIIa does not activate FXI in vivo. Indeed, FXIIa-mediated activation of FXI appears to play a central role in formation of pathologic thrombi in murine thrombosis models.33,38 Naito and Fujikawa13 and von dem Borne et al15 were the rst to present results indicating that FXI is activated by thrombin in plasma. In puried protein systems, FXI activation by thrombin is enhanced by charged substances, such as dextran sulfate or heparin,13,14 but the relevance to activation in vivo is not clear. Thrombin interacts with most of its substrates through 2 electropositive anion-binding exosites (ABE I and ABE II).79 Using a panel of thrombins with site-specic mutations, Yun et al showed that ABE I and ABE II are required for efcient FXI activation in the presence of dextran sulfate.80 Here ABE II interacts with dextran sulfate, whereas ABE I probably binds FXI. Recent experiments in plasma, however, did not identify a role for ABE I in FXI activation, as wild-type thrombin and thrombin with mutations in ABE I initiated FXI-dependent thrombin generation similarly.81 Available information indicates that thrombin binds to the A1 domain of FXI, with residues Glu66, Lys83, and Gln84 forming part of the binding site.7,57,75 These residues cluster near the interface with the A4 domain (Figures 2B, 3A) and are suitably positioned in proximity to the activation loop containing the Arg369-Ile370 cleavage site. The FXI residues involved in binding FXIIa have not been denitively determined, and the interaction may extend beyond a single apple domain surface. For example, although studies using peptide mimicry point to a binding site for FXIIa on the A4 domain,82 a monoclonal antibody that recognizes A2 selectively interferes with FXI activation by FXIIa.76,81 A role for the FXI dimer in promoting zymogen activation by thrombin in trans has been proposed.7 Here the activating protease would bind one subunit of the dimer and cleave Arg369-Ile370 on the other. Consistent with this, Wu et al used a series of recombinant monomeric FXI proteins in a puried system to show that the dimer is required for optimal FXI activation by thrombin, FXIIa, and FXIa.50 Some of these studies used dextran sulfate to facilitate FXI activation, which may not suitably model the physiologic environment. A second

Figure 5. FXI activation. Each FXI subunit is activated by cleavage between Arg369 and Ile370. FXI (0-hour time point) migrates slightly faster than FXIa (top band, 6 hours) on nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Activation of FXI (schematic at left) by -thrombin (shown) or FXIIa proceeds through an intermediate with 1 cleaved subunit (center), designated 1/2-FXIa. Subsequent conversion of 1/2-FXIa to fully activated FXIa (right) appears to be a slower process. In the diagrams, the A1, A2, A3, and A4 domains are shown in light blue, cyan, orange, and yellow, respectively, and the catalytic domains (CAT) are in white. Circles represent unactivated catalytic domains; three-fourths circles, activated catalytic domains. In these diagrams, the catalytic domain moves relative to the apple domain disk after cleavage of Arg369-Ile370, exposing a surface on A3 thought to contain a FIX-binding site.

From bloodjournal.hematologylibrary.org by guest on July 19, 2013. For personal use only.
BLOOD, 1 APRIL 2010 VOLUME 115, NUMBER 13 FACTOR XI STRUCTURE AND FUNCTION 2573

ligand

B Recognition and cleavage of FIX by FXIa

FXIas major substrate, FIX, has an elongated structure that includes (from the N-terminus) a calcium-binding Gla domain, 2 EGF repeats, a 55-amino acid activation peptide, and a Cterminal serine protease domain (Figure 7A).90 Conversion of FIX to the protease FIXa requires cleavages of the Arg145-Ala146 and Arg180-Val181 bonds releasing the activation peptide. When FIX is activated by the factor VIIa (FVIIa)/TF complex (Figure 1), there is preference for initial cleavage after Arg145, resulting in accumulation of the intermediate FIX, followed by cleavage after Arg180 (Figure 7B).91-93 In contrast, relatively little or no FIX accumulates during FIX activation by FXIa (Figure 7C).50,94-96 More than 1 mechanism is compatible with this observation. Cleavage of the FIX activation sites by FXIa could be sequential, with the rate of the second cleavage greater than the rst. Indeed, FXIa, like FVIIa/TF, cleaves FIX initially at the Arg145-Ala146 bond.83,96 Alternatively, the protease may cleave sequentially but not release the intermediate before the second cleavage. This is consistent with data showing that cleavage rates of FIX and FIX by FXIa are roughly similar (ie, Arg180-Val181 is not cleaved more rapidly than Arg145-Ala146).95 The possibility that FXIa requires its 2 catalytic domains to cleave the FIX activation sites simultaneously has been refuted, as 1/2-FXIa83 and monomeric variants of FXIa50 activate FIX similarly to dimeric FXIa. Initial recognition of FIX involves exosites on FXIa that are distinct from the catalytic active site.96-98 FIX does not bind FXI,99 indicating that conformational changes during conversion of FXI to FXIa expose the exosites. An antibody that recognizes an epitope on the FXIa apple domain disk competitively inhibited FIX activation by FXIa.98 Subsequent work with recombinant proteins localized a FIX-binding site to the A3 domain (Figures 2B, 3).62,63 A critical residue for FIX activation is Arg184,63 located near the N-terminus of A3. An Arg184Gly mutation was recently reported in a CRM FXI-decient patient, and recombinant FXIa with this mutation activates FIX poorly.100 In the zymogen structure, Arg184 occupies a central location in a loop connecting A2 and A3 that is buried under the protease domain (Figure 6A,C). The long Arg side

R489 I370 R184

R184
Figure 6. The FXIa protease domain. (A) Topologic diagram showing the superposition of FXI (white) and FXIa (red) protease domain crystal structures. Conformational changes include a 12 shift in the position of Ile370 into the protease core after cleavage of the Arg369-Ile370 bond, and an unraveling of an -helix containing Arg489 to ll a pocket left empty by removal of the A3 domain and Arg184. The Arg side chain from the FXIa ligand in panel B is shown in blue. (B) Structure of FXIa in complex with PN2-KPI domain inhibitor (blue). (C) The side chain of Arg184 is buried in the FXI zymogen through contacts with the protease domain. This residue is thought to act as a switch, which is released on zymogen activation to engage substrate FIX. (D) Stick diagram showing the side chain of Arg184 that forms 3 noncovalent interactions with the side chains of Ser268 (gray) from the A3 domain, and Asp488 (green) and Asn566 (white) from the protease domain in the FXI zymogen structure.

change to substrate recognition is discussed in Recognition and cleavage of FIX by FXIa. Activated FXIa is subject to negative regulation by plasma serpins, including antithrombin, C1-inhibitor, protease nexin 1, and protein Zdependent protease inhibitor.59-61,84-87 Basic amino acids in the autolysis loop of the catalytic domain (Arg504, Lys505, Arg507, and Lys509) are determinants of serpin specicity.87 Heparin enhances serpin-mediated FXIa inhibition through a mechanism involving heparin-binding sites on the A3 (Lys252, Lys253, and Lys 255; Figures 2B, 3)58,59 and catalytic (Lys529, Arg530, Arg532, Lys536, and Lys540)61,62 domains (Figure 3). The A3-binding site facilitates inhibition through a template mechanism in which both protease and serpin bind to heparin.61 In contrast, heparin binding to the catalytic domain facilitates inhibition in a manner not completely explained by a template mechanism, and probably involves charge neutralization or an allosteric effect that overcomes repulsive interactions between the serpin and catalytic domain.61 FXIa is also regulated by protease nexin 2 (PN2),41,88,89 which is released from activated platelets.88 FXIa inhibition requires the Kunitz-type protease inhibitor (KPI) domain of PN2. A crystal structure of the FXIa catalytic domain complex with PN2-KPI shows that the inhibitor has a characteristic disulde-stabilized double-loop structure that ts into the FXIa active site, with the P1 arginine occupying the S1-binding pocket (Figure 6B).41

Figure 7. FIX activation. (A) FIX contains (from the N-terminus) a Gla domain (green), 2 epidermal growth factor (EGF) domains (red), an activation peptide (AP; gray bar), and a catalytic (CAT) domain (white). FIX is converted to FIXa by cleavage after Arg145 and Arg180, releasing the AP. FVIIa/TF initially cleaves FIX after Arg145 to form the intermediate FIX, with subsequent cleavage after Arg180 to form FIXa (bold arrows). White three-fourths circle represents the active catalytic domain of FIXa. During this reaction, FIX accumulates before formation of FIXa. FXIa also cleaves FIX initially after Arg145; however, no FIX accumulates. Initial cleavage of zymogen FIX after Arg180 to generate the intermediate FIXa appears to be a minor reaction (thin arrows). (B-C) Reducing Western blots of FIX (100nM) activated by 1nM FVIIa/TF (B) or FXIa (C) over 30 minutes (time indicated between panels). Markers at the right indicate migration of standards for zymogen FIX (FIX), the large fragment of FIX (FIX), the heavy chain (HC) of FIXa, and the light chain (LC) of FIX or FIXa. No FIX accumulates during activation by FXIa.

From bloodjournal.hematologylibrary.org by guest on July 19, 2013. For personal use only.
2574 EMSLEY et al BLOOD, 1 APRIL 2010 VOLUME 115, NUMBER 13

chain extends such that the guanidinium group lls the small pocket formed by the interface between the apple domains and catalytic domain. Here, Arg184 interacts with 3 residues: 2 from the catalytic domain (Asp488, Asn566) and 1 from the A3 domain (Ser268; Figure 6D). Arg184 is conserved in FXI across species12 but is not present in PK, consistent with its role in interactions with FIX. The Arg184 side chain must be exposed in FXIa by conformational changes that occur after cleavage of the Arg369-Ile370 bond in the activation loop. Full-length FXI and FXIa have been analyzed by small-angle x-ray scattering and electron microscopy, which revealed a change in the shape of the molecule on activation, consistent with a shift in the position of the apple domain disk relative to the catalytic domain.43 This could break interactions between Arg184 and Asp488, Asn566, and Ser268 (Figure 6D). Arg184 may, therefore, be part of a switch that holds FXI in an inactive conformation in the zymogen and, when the switch is thrown, facilitates engagement of FIX. It appears that residues in the FIX Gla domain are required for binding to FXIa,99 explaining the enhancing effect of calcium ions on the reaction.90 There is also evidence that it is the Gla domain that binds to the A3 domain.101 Interestingly, loss of the A3 exosite has a more deleterious effect on cleavage of FIX at Arg180-Val181 than at Arg145-Ala146.83,96 This suggests that the A3 exosite primarily facilitates cleavage of FIX to FIXa96 and that a distinct exosite is involved in the initial interaction with FIX that facilitates conversion to FIX. Recent work by Sinha et al indicates that this exosite is located on the FXIa catalytic domain.96 Interestingly, unlike binding to the A3 exosite, the interaction with the catalytic domain exosite does not required calcium, suggesting that the interaction does not involve the FIX Gla domain.

R250 S248

Figure 8. Platelet-binding site on FXI. The locations of 2 residues (Ser248 and Arg250 in black), that probably form a GPIb platelet-binding site on the FXI A3 domain (orange), are shown relative to residues that form the heparin-binding site (Ly252, Lys253, and Lys255 in blue). Ser248 forms hydrogen bonds with Asp194 and Thr249, which are probably disrupted in the hereditary FXI mutation Ser248Gln. The adjacent A2 domain is shown in light blue. The position of an N-linked glycan moiety attached to residue Asn108 of the A2 domain is shown in yellow and red.

FXI interactions with platelet receptors

Although platelets do not appear to enhance FXI activation in a static system,75 there is growing evidence that platelets affect FXI and FXIa behavior under ow.35,70 When human blood lacking FXII activity is perfused over collagen at arterial shear rates, platelets deposit in aggregates and brin strands form.70 Addition of an antibody that blocks FXIa activation of FIX prevents brin formation. Interestingly, adding inhibitors of FVIIa/TF does not affect brin formation, suggesting that platelets may play a role in FXI activation. Platelets may also localize FXIa to the site of brin formation, as brin does not form when blood lacking platelets is perfused over collagen. FXI lacks the Gla domain that facilitates binding of vitamin K-dependent coagulation proteases to phospholipid surfaces.5-7 Yet, there is solid evidence that FXI binds to platelets. Greengard et al measured approximately 1500 binding sites for FXI per activated platelet.67 Subsequent work determined that platelet GP1b mediates binding and that FXI competes with von Willebrand factor, but not thrombin, for binding to GP1b.102 Optimal binding of FXI to platelets requires residues in the FXI A3 domain (Figures 2B, 3),64,68,69 the N-terminal domain of the GP1b chain,102 HK, and zinc ions.67-69 The A3 residues involved, Ser248 and Arg250, are near to, but distinct from, the A3 heparin-binding site.58,59 A CRM missense mutation in the A3 domain, Ser248Asn, was identied in a family with a bleeding disorder.103 FXI-Asn248 binds platelets with 5-fold reduced afnity compared with wild-type FXI,103 and other Ser248 substitutions (Gln or Ala) showed similar defects.104 Figure 8 shows the local environment around Ser248. The overall structure of the A3 domain is probably not affected signicantly by

the Ser248Asn mutation, as FXI-Asn248 is (1) secreted, (2) activated by FXIIa, and (3) activates FIX similar to wild-type FXIa. Cumulatively, the ndings make it probable that Ser248 and Arg250 are central to a site for interactions with platelet GPIb. FXIa also binds to platelets ( 250 sites per platelet) but does so by a mechanism that appears to differ from that of FXI.105 FXIa binding to platelets does not require the A3 domain or HK, and involves residues in the catalytic domain between Cys527 and Cys542 in the vicinity of the heparin-binding site (Figure 3).106 The binding site on platelets for FXIa has not been identied but appears to be distinct from that of FXI, as FXI does not compete with FXIa for binding.105 The observation that each platelet contains 1500 FXI-binding sites was somewhat perplexing, considering that there are approximately 25 000 copies of GP1b per platelet.107 New data from White-Adams et al may offer a solution to this conundrum; this group reported that FXI binds to a platelet receptor for apolipoprotein E called ApoER2 or LRP8.70 FXI binds to soluble ApoER2 with an afnity of approximately 60nM. Human and murine platelets bind and spread on glass coated with FXI or brinogen. Binding to FXI, but not brinogen, was abrogated by receptorassociated protein, which blocks ligand binding to members of the low-density lipoprotein receptor family. Platelet binding to FXI was also blocked by soluble ApoER2, and platelets from ApoER2decient mice did not bind FXI. Under conditions of physiologic shear, soluble ApoER2 or its low-density lipoprotein-binding domain prevented platelet binding to immobilized FXI. There are an estimated 2000 copies of ApoER2 per platelet, which agrees well with the number of FXI-binding sites.67 Furthermore, ApoER2 colocalizes with GP1b on platelets,108 suggesting that FXI binding involves both receptors. Consistent with this, antibodies to GP1b block platelet binding to immobilized FXI under physiologic shear. It is not clear whether the platelet-binding site on the FXI A3 domain is required for interactions with ApoER2 or whether a different site is involved.

Future directions
Several important aspects of FXI pathophysiology require additional study. Over the past 50 years, many investigators have

From bloodjournal.hematologylibrary.org by guest on July 19, 2013. For personal use only.
BLOOD, 1 APRIL 2010 VOLUME 115, NUMBER 13 FACTOR XI STRUCTURE AND FUNCTION 2575

commented on the weak correlation between bleeding and FXI activity measured by conventional assays. This is reected in 2 studies involving 49 FXI-decient kindreds (242 persons), which determined that severity of bleeding was similar in patients with severe and mild deciency.21,22 In contrast, work with patients primarily with the Glu117Stop and/or Phe283Leu mutations showed bleeding risk to be much greater in severe than mild deciency (odds ratio 13.0 and 2.6, respectively).109 Diverse factors could be contributing to this disagreement, including differences in clinical criteria for bleeding, variation in genetic backgrounds or FXI mutations, or coinheritance of other bleeding disorders. That being said, some patients with severe FXI deciency do not bleed abnormally, even with trauma to tissues that typically cause problems for FXI-decient patients. We suspect that the manner in which we measure FXI activity in clinical laboratories does not accurately assess the proteins contribution to hemostasis. FXI-decient plasma exhibits a prolonged aPTT clotting time, and FXI deciency is currently dened as low activity in an aPTT-based assay in which patient and FXI-decient plasma are mixed. However, the aPTT only requires FXI to function as a component of contact activation initiated brin formation, and does not assess FXI functions such as feedback activation by thrombin, inhibition of brinolysis, and interactions with platelets. The FXI Ser248Asn variant illustrates the limitations of the aPTT in assessing FXI function. This mutation is associated with bleeding and defective FXI binding to platelets but does not affect the aPTT assay, which does not contain platelets.103 Assays that capture the importance of FXI to sustained (rather than initial) thrombin generation, probably in platelet-rich plasma under ow, will be required to address the deciencies of the aPTT. Allen et al made the interesting observation that the contribution of FXI to thrombin generation varied substantially when platelets from different normal donors were tested in a cell-based model of TF-initiated coagulation.110 Platelets, therefore, may turn out to be key for accurately assessing FXI function. As presented in this review, FXI has features that distinguish it from vitamin Kdependent coagulation proteases, making it difcult to extrapolate from the lessons learned from the large body of work on these enzymes to predict structure-function relationships for FXI. There remain many important unanswered questions regarding FXI and FXIa from a structural and enzymologic perspective. Areas of active investigation include determining the functional signicance of the dimeric structure of FXI/FXIa, elucidating the manner in which FXI/FXIa engages platelets, and identifying the functional consequences of platelet binding. New evidence indicates that the dimeric structure of FXI facilitates its activation by FXIIa and thrombin.50 However, the FXI homolog PK (a monomer) is activated rapidly by FXIIa, as is a monomeric FXI chimera containing the PK A4 domain.62 It will be

important to determine whether dimerization is critical for FXI activation under physiologic conditions, probably using ow-based systems, or perhaps in vivo. It has been proposed that one subunit of a FXIa dimer could bind to a platelet receptor, leaving the other free to interact with the substrate FIX.105 An intriguing possibility that remains to be tested is that 1/2-FXIa binds to GP1b, or perhaps ApoER2, through the A3 domain of its unactivated subunit while binding to FIX through A3 on the activated subunit. Note that in Figure 3B the A3 domains point in opposite directions from the longitudinal plane of the molecule. As FXI lacks a Gla domain, the dimeric structure may represent an alternative solution to the problem of tethering the protease to a surface at a wound site while allowing interaction with its substrate. Such a hypothesis is also best tested in ow-based systems, where the FXI-platelet interaction is probably important to protease function. Recent studies associating FXIa activity and pathologic coagulation in humans and animal models have stimulated considerable interest in this protease as a target for clinical intervention, with potential advantages over targeting thrombin or FXa in terms of side effects and therapeutic window. Work on FXI structure is at an early stage, compared with the vitamin K-dependent coagulation factors, with crystal structural data becoming available only within the past 5 years. Structures dening full-length FXIa and ligand complexes with substrate, receptors, and activating enzymes will be required to completely understand the molecular basis of processes such as zymogen activation, platelet binding, and substrate cleavage. This will be critical to understanding the role of this protease in disease processes and to the development of specic inhibitors for clinical purposes.

Acknowledgments
This work was supported by the British Heart Foundation (grants PG/04/129/18095 and RG/07/002/23132; J.E.) and the National Heart, Lung, and Blood Institute (awards HL58837 and HL81326; D.G.).

Authorship
Contribution: J.E., P.A.M., and D.G. wrote the paper. Conict-of-interest disclosure: The authors declare no competing nancial interests. Correspondence: Jonas Emsley, Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, United Kingdom; e-mail: jonas.emsley@ nottingham.ac.uk; or David Gailani, Hematology/Oncology Division, Vanderbilt University School of Medicine, Nashville, TN 37232; e-mail: dave.gailani@vanderbilt.edu.

References
1. Furie B, Furie BC. Molecular basis of blood coagulation. In: Hoffman H, Benz EJ, Shattil SJ, et al, eds. Hematology, Basic Principles and Practice, 5th ed. Philadelphia, PA: Churchill Livingstone-Elsevier. 2009:1819-1836. 2. Seligsohn U. Factor XI in haemostasis and thrombosis: past, present and future. Thromb Haemost. 2007;98(1):84-89. 3. Gailani D, Smith SB. Structural and functional features of factor XI. J Thromb Haemost. 2009; 7[suppl 1]:75-78. 4. Bouma BN, Grifn JH. Human blood coagulation factor XI: purication, properties, and mechanism of activation by activated factor XII. J Biol Chem. 1977;252(18):6432-6437. 5. Fujikawa K, Chung DW, Hendrickson LE, Davie EW. Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry. 1986;25(9):2417-2424. 6. McMullen BA, Fujikawa K, Davie EW. Location of the disulde bonds in human coagulation factor XI: the presence of tandem apple domains. Biochemistry. 1991;30(8):2056-2060. 7. Papagrigoriou E, McEwan PA, Walsh PN, Emsley J. Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol. 2006;13(6):557-558. 8. Thompson RE, Mandle R Jr, Kaplan AP. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest. 1977;60(6):1376-1380. 9. McMullen BA, Fujikawa K, Davie EW. Location of the disulde bonds in human plasma prekallikrein: the presence of four novel apple domains in the amino-terminal portion of the molecule. Biochemistry. 1991;30(8):2050-2056.

From bloodjournal.hematologylibrary.org by guest on July 19, 2013. For personal use only.
2576 EMSLEY et al BLOOD, 1 APRIL 2010 VOLUME 115, NUMBER 13

10. Hooley E, McEwan PA, Emsley J. Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation. J Thromb Haemost. 2007;5(12):2461-2466. 11. Mandle RJ, Colman RW, Kaplan AP. Identication of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci U S A. 1976;73(11):4179-4183. 12. Ponczek MB, Gailani D, Doolittle RF. Evolution of the contact phase of vertebrate blood coagulation. J Thromb Haemost. 2008;6(11):1876-1883. 13. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII: factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem. 1991;266(12):7353-7358. 14. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science. 1991;253(5022):909-912. 15. von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects brin clots from brinolysis. Blood. 1995;86(8):3035-3042. 16. Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deciency in Ashkenazi Jews in Israel. N Engl J Med. 1991;325(3):153-158. 17. Seligsohn U. Factor XI deciency in humans. J Thromb Haemost. 2009;7[suppl 1]:84-87. 18. Bouma BN, Meijers JC. New insights into factors affecting clot stability: a role for thrombin activatable brinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R). Semin Hematol. 2004;41[suppl 1]:13-19. 19. Nesheim M, Bajzar L. The discovery of TAFI. J Thromb Haemost. 2005;3(10):2139-2146. 20. Mosnier LO, Bouma BN. Regulation of brinolysis by thrombin activatable brinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and brinolysis. Arterioscler Thromb Vasc Biol. 2006;26(11):2445-2453. 21. Ragni MV, Sinha D, Seaman F, Lewis JH, Spero JA, Walsh PN. Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-decient kindreds. Blood. 1985; 65(3):719-724. 22. Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, Slack J, Kernoff PB. Inheritance and bleeding in factor XI deciency. Br J Haematol. 1988;69(4): 521-528. 23. Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Denition of the bleeding tendency in factor XI-decient kindreds: a clinical and laboratory study. Thromb Haemost. 1995; 73(2):194-202. 24. Peretz H, Mulai A, Usher S, et al. The two common mutations causing factor XI deciency in Jews stem from distinct founders: one of ancient Middle Eastern origin and another of more recent European origin. Blood. 1997;90(7):2654-2659. 25. Asakai R, Chung DW, Ratnoff OD, Davie EW. Factor XI (plasma thromboplastin antecedent) deciency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci U S A. 1989;86:76677671. 26. Meijers JC, Davie EW, Chung DW. Expression of human blood coagulation factor XI: characterization of the defect in factor XI type III deciency. Blood. 1992;79(6):1435-1440. 27. Kravtsov DV, Wu W, Meijers JC, et al. Dominant factor XI deciency caused by mutations in the factor XI catalytic domain. Blood. 2004;104(1): 128-134. 28. Riley PW, Cheng H, Samuel D, Roder H, Walsh PN. Dimer dissociation and unfolding mechanism of coagulation factor XI apple 4 domain: spectroscopic and mutational analysis. J Mol Biol. 2007; 367(2):558-573.

29. Saunders RE, Shiltagh N, Gomez K, et al. Structural analysis of eight novel and 112 previously reported missense mutations in the interactive FXI mutation database reveals new insight on FXI deciency. Thromb Haemost. 2009;102(2): 287-301. 30. Gailani D, Neff AT. Rare coagulation factor deciencies. In: Hoffman H, Benz EJ, Shattil SJ, et al, eds. Hematology, Basic Principles and Practice, 5th ed. Philadelphia, PA: Churchill Livingstone-Elsevier; 2009:1939-1952. 31. Saito H, Ratnoff OD, Bouma BN, Seligsohn U. Failure to detect variant (CRM) plasma thromboplastin antecedent (factor XI) molecules in hereditary plasma thromboplastin antecedent deciency: a study of 125 patients of several ethnic backgrounds. J Lab Clin Med. 1985;106(6):718722. 32. Wang X, Cheng Q, Xu L, et al. Effects of factor IX or factor XI deciency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost. 2005;3(4):695-702. 33. Renne T, Pozgajova M, Gru ner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271-281. 34. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood. 2006; 108(13):4045-4051. 35. Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombusassociated thrombin generation by inhibition of factor XI. Blood. 2009;113(4):936-944. 36. Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deciency. Blood. 2008;111(8):4113-4117. 37. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342(10):696-701. 38. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006;203(3):513-518. 39. Tucker EI, Gailani D, Hurst S, Cheng Q, Hanson SR, Gruber A. Survival advantage of coagulation factor XI-decient mice during peritoneal sepsis. J Infect Dis. 2008;198(2):271-274. 40. Jin L, Pandey P, Babine RE, et al. Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions. J Biol Chem. 2005;280(6):4704-4712. 41. Navaneetham D, Jin L, Pandey P, et al. Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2. J Biol Chem. 2005;280(43):3616536175. 42. Jin L, Pandey P, Babine RE, Weaver DT, AbdelMeguid SS, Strickler JE. Mutation of surface residues to promote crystallization of activated factor XI as a complex with benzamidine: an essential step for the iterative structure-based design of factor XI inhibitors. Acta Crystallogr D Biol Crystallogr. 2005;61(10):1418-1425. 43. Samuel D, Cheng H, Riley PW, et al. Solution structure of the A4 domain of factor XI sheds light on the mechanism of zymogen activation. Proc Natl Acad Sci U S A. 2007;104(10):15693-15698. 44. Tordai H, Ba nyai L, Patthy L. The PAN module: the N-terminal domains of plasminogen and hepatocyte growth factor are homologous with the apple domains of the prekallikrein family and with a novel domain found in numerous nematode proteins. FEBS Lett. 1999;461(1):63-67. 45. Huizinga EG, Schouten A, Connolly TM, Kroon J, Sixma JJ, Gros P. The structure of leech antiplatelet protein, an inhibitor of haemostasis. Acta

Crystallogr D Biol Crystallogr. 2001;57(8):10711078. 46. Brown PJ, Gill AC, Nugent PG, McVey JH, Tomley FM. Domains of invasion organelle proteins from apicomplexan parasites are homologous with the Apple domains of blood coagulation factor XI and plasma pre-kallikrein and are members of the PAN module superfamily. FEBS Lett. 2001;497(1):31-38. 47. Meijers JC, Mulvihill ER, Davie EW, Chung DW. Apple four in human blood coagulation factor XI mediates dimer formation. Biochemistry. 1992; 31(19):4680-4684. 48. Dorfman R, Walsh PN. Noncovalent interactions of the Apple 4 domain that mediate coagulation factor XI homodimerization. J Biol Chem. 2001; 276(9):6429-6438. 49. Cheng Q, Sun MF, Kravtsov DV, Aktimur A, Gailani D. Factor XI apple domains and protein dimerization. J Thromb Haemost. 2003;1(11): 2340-2347. 50. Wu W, Sinha D, Shikov S, et al. Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa. J Biol Chem. 2008;283(27):18655-18664. 51. Zucker M, Zivelin A, Landau M, Rosenberg N, Seligsohn U. Three residues at the interface of factor XI (FXI) monomers augment covalent dimerization of FXI. J Thromb Haemost. 2009; 7(6):97097-97105. 52. Bodo I, Katsumi A, Tuley E, Eikenboom J, Dong Z, Sadler J. Type I von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible mechanism for dominant mutations in oligomeric proteins. Blood. 2001;98(10):2973-2979. 53. Brennan S, Wyatt J, Medicina D, Callea F, George P. Fibrinogen brescia: hepatic endoplasmic reticulum storage and hypobrinogenemia because of gamma 284 Gly 3 Arg mutation. Am J Pathol. 2000;157(1):189-196. 54. Kravtsov DV, Monahan PE, Gailani D. A classication system for cross-reactive material-negative factor XI deciency. Blood. 2005;105(12):46714673. 55. Renne T, Gailani D, Meijers JC, Mu ller-Esterl W. Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein. J Biol Chem. 2002;277(7): 4892-4899. 56. Renne T, Sugiyama A, Gailani D, JahnenDechent W, Walter U, Mu ller-Esterl W. Fine mapping of the H-kininogen binding site in plasma prekallikrein apple domain 2. Int Immunopharmacol. 2002;2(13):1867-1873. 57. Baglia FA, Walsh PN. A binding site for thrombin in the apple 1 domain of factor XI. J Biol Chem. 1996;271(7):3652-3658. 58. Ho DH, Badellino K, Baglia FA, Walsh PN. A binding site for heparin in the apple 3 domain of factor XI. J Biol Chem. 1998;273(26):16382-16390. 59. Zhao M, Abdel-Razek T, Sun MF, Gailani D. Characterization of a heparin-binding site on the heavy chain of factor XI. J Biol Chem. 1998; 273(47):31153-31159. 60. Badellino KO, Walsh PN. Localization of a heparinbinding site in the catalytic domain of factor XIa. Biochemistry. 2001;40:7569-7580. 61. Yang L, Sun MF, Gailani D, Rezaie AR. Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor. Biochemistry. 2009;48:1517-1524. 62. Sun Y, Gailani D. Identication of a factor IX binding site on the third apple domain of activated factor XI. J Biol Chem. 1996;271(46):29023-29028. 63. Sun MF, Zhao M, Gailani D. Identication of amino acids in the factor XI apple 3 domain required for activation of factor IX. J Biol Chem. 1999;274(51):36373-36378.

From bloodjournal.hematologylibrary.org by guest on July 19, 2013. For personal use only.
BLOOD, 1 APRIL 2010 VOLUME 115, NUMBER 13 FACTOR XI STRUCTURE AND FUNCTION 2577

64. Baglia FA, Gailani D, Lo pez JA, Walsh PN. Identication of a binding site for glycoprotein Ib-alpha in the Apple 3 domain of factor XI. J Biol Chem. 2004;279(44):45470-45476. 65. Sainz IM, Pixley RA, Colman RW. Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost. 2007;98(1):77-83. 66. Scott CF, Colman RW. Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. J Clin Invest. 1980; 65(2):413-421. 67. Greengard JS, Heeb MJ, Ersdal E, Walsh PN, Grifn JH. Binding of coagulation factor XI to washed human platelets. Biochemistry. 1986; 25(13):3884-3890. 68. Baglia FA, Jameson BA, Walsh PN. Identication and characterization of a binding site for platelets in the Apple 3 domain of coagulation factor XI. J Biol Chem. 1995;270(12):6734-6740. 69. Baglia FA, Gailani D, Lopez JA, Walsh PN. Identication of a binding site for glycoprotein Ib in the apple 3 domain of factor XI. J Biol Chem. 2004; 279(44):45470-45476. 70. White-Adams TC, Berny MA, Tucker EI, et al. Identication of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). Arterioscler Thromb Vasc Biol. 2009;29(10):16021607. 71. Baglia FA, Jameson BA, Walsh PN. Fine mapping of the high molecular weight kininogen binding site on blood coagulation factor XI through the use of rationally designed synthetic analogs. J Biol Chem. 1992;267(6):4247-4252. 72. Mitchell M, Harrington P, Cutler J, Rangarajan S, Savidge G, Alhaq A. Eighteen unrelated patients with factor XI deciency, four novel mutations and a 100% detection rate by denaturing high-performance liquid chromatography. Br J Haematol. 2003;121(3): 500-502. 73. OConnell NM, Saunders RE, Lee CA, Perry DJ, Perkins SJ. Structural interpretation of 42 mutations causing factor XI deciency using homology modeling. J Thromb Haemost. 2005;3(1):127138. 74. Katsuda I, Maruyama F, Ezaki K, Sawamura T, Ichihara Y. A new type of plasma prekallikrein deciency associated with homozygosity for Gly104Arg and Asn124Ser in apple domain 2 of the heavy-chain region. Eur J Haematol. 2007; 79(1):59-68. 75. Kravtsov DV, Matafonov A, Tucker EI, et al. Factor XI contributes to thrombin generation in the absence of factor XII. Blood. 2009;114(2):452458. 76. von dem Borne PA, Mosnier LO, Tans G, Meijers JC, Bouma BN. Factor XI activation by meizothrombin: stimulation by phospholipid vesicles containing both phosphatidylserine and phosphatidylethanolamine. Thromb Haemost. 1997; 78(2):834-839. 77. Spronk HMH, Wilhelm S, Heemskerk H, et al. Feedback activation of factor XI by thrombin is essential for haemostasis in vivo. J Thromb Haemost. 2009;7[suppl 2]:Abstract PL-TU-003. 78. Pawlinski R, Pedersen B, Erlich J, Mackman N. Role of tissue factor in haemostasis, thrombosis, angiogenesis and inammation: lessons from low tissue factor mice. Thromb Haemost. 2004;92(3): 444-450. 79. Crawley JT, Zanardelli S, Chion CK, Lane DA.

The central role of thrombin in hemostasis. J Thromb Haemost. 2007;5[suppl 1]:95-101. 80. Yun TH, Baglia FA, Myles T, et al. Thrombin activation of factor XI on activated platelets requires the interaction of factor XI and platelet glycoprotein Ib alpha with thrombin anion-binding exosites I and II, respectively. J Biol Chem. 2003;278(48): 48112-48119. 81. Matafonov A, Kravtsov DV, Tucker EI, et al. Factor XI contributes to thrombin generation in the absence of factor XIIa. Blood. 2008;112(11): 1058a-1059a. 82. Baglia FA, Jameson BA, Walsh PN. Identication and characterization of a binding site for factor XIIa in the Apple 4 domain of coagulation factor XI. J Biol Chem. 1993;268(6):3838-3844. 83. Smith SB, Verhamme IM, Sun MF, Bock PE, Gailani D. Characterization of novel forms of coagulation factor XIa: independence of factor XIa subunits in factor IX activation. J Biol Chem. 2008;283(11):6696-6705. 84. Wuillemin WA, Hack CE, Bleeker WK, Biemond BJ, Levi M, ten Cate H. Inactivation of factor XIa in vivo: studies in chimpanzees and in humans. Thromb Haemost. 1996;76(4):549-555. 85. Knauer DJ, Majumdar D, Fong PC, Knauer MF. SERPIN regulation of factor XIa: the novel observation that protease nexin 1 in the presence of heparin is a more potent inhibitor of factor XIa than C1 inhibitor. J Biol Chem. 2000;275(48): 37340-37346. 86. Rezaie AR, Sun MF, Gailani D. Contributions of basic amino acids in the autolysis loop of factor XIa to serpin specicity. Biochemistry. 2006; 45(31):9427-9433. 87. Zhang J, Tu Y, Lu L, Lasky N, Broze GJ. Protein Z-dependent protease inhibitor deciency produces a more severe murine phenotype than protein Z deciency. Blood. 2008;111(10):4973-4978. 88. Smith RP, Higuchi DA, Broze GJ. Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science. 1990; 248(4959):1126-1128. 89. Scandura JM, Zhang Y, Van Nostrand WE, Walsh PN. Progress curve analysis of the kinetics with which blood coagulation factor XIa is inhibited by protease nexin-2. Biochemistry. 1997;36(2):412420. 90. Schmidt AE, Bajaj SP. Structure-function relationships in factor IX and factor IXa. Trends Cardiovasc Med. 2003;13(1):39-45. 91. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A. 1977;74(12): 5260-5264. 92. Bajaj SP, Rapaport SI, Russell WA. Redetermination of the rate-limiting step in the activation of factor IX by factor XIa and by factor VIIa/tissue factor: explanation for different electrophoretic radioactivity proles obtained on activation of 3Hand 125I-labeled factor IX. Biochemistry. 1983; 22(17):4047-4053. 93. Lawson JH, Mann KG. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem. 1991;266(17): 11317-11327. 94. Osterud B, Bouma BN, Grifn JH. Human blood coagulation factor IX: purication, properties, and mechanism of activation by activated factor XI. J Biol Chem. 1978;253(17):5946-5951. 95. Wolberg AS, Morris DP, Stafford DW. Factor IX

activation by factor XIa proceeds without release of a free intermediate. Biochemistry. 1997;36(14): 4074-4079. 96. Sinha D, Marcinkiewicz M, Navaneetham D, Walsh PN. Macromolecular substrate-binding exosites on both the heavy and light chains of factor XIa mediate the formation of the Michaelis complex required for factor IX-activation. Biochemistry. 2007;46(34):9830-9839. 97. Ogawa T, Verhamme IM, Sun MF, Bock PE, Gailani D. Exosite-mediated substrate recognition of factor IX by factor XIa: the factor XIa heavy chain is required for initial recognition of factor IX. J Biol Chem. 2005;280(25):23523-23530. 98. Sinha D, Seaman FS, Walsh PN. Role of calcium ions and the heavy chain of factor XIa in the activation of human coagulation factor IX. Biochemistry. 1987;26(13):3768-3775. 99. Aktimur A, Gabriel MA, Gailani D, Toomey JR. The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa. J Biol Chem. 2003;278(10): 7981-7987. 100. Guella I, Solda ` G, Spena S, et al. Molecular characterization of two novel mutations causing factor XI deciency: a splicing defect and a missense mutation responsible for a CRM defect. Thromb Haemost. 2008;99(3):523-530. 101. Gailani D, Smith SB, Agah S, Bajaj SP. An analysis of cleavage of the factor IX activation sites by factor XIa. Blood. 2008;112(11):1060a. 102. Baglia FA, Shrimpton CN, Emsley J, et al. Factor XI interacts with the leucine-rich repeats of glycoprotein Ibalpha on the activated platelet. J Biol Chem. 2004;279(47):49323-49329. 103. Sun MF, Baglia FA, Ho D, et al. Defective binding of factor XI-N248 to activated human platelets. Blood. 2001;98(1):125-129. 104. Ho DH, Badellino K, Baglia FA, et al. The role of high molecular weight kininogen and prothrombin as cofactors in the binding of factor XI A3 domain to the platelet surface. J Biol Chem. 2000; 275(33):25139-25145. 105. Sinha D, Seaman FS, Koshy A, Knight LC, Walsh PN. Blood coagulation factor XIa binds specically to a site on activated human platelets distinct from that for factor XI. J Clin Invest. 1984; 73(6):1550-1556. 106. Miller TN, Sinha D, Baird TR, Walsh PN. A catalytic domain exosite (Cys527-542) in factor XIa mediates binding to a site on activated platelets. Biochemistry. 2007;46(50):14450-14460. 107. Bergmeier W, Chauhan AK, Wagner DD. Glycoprotein Ibalpha and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb Haemost. 2008;99(2):264-270. 108. Pennings MT, Derksen RH, van Lummel M, et al. Platelet adhesion to dimeric beta-glycoprotein I under conditions of ow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2. J Thromb Haemost. 2007;5(2):369-377. 109. Brenner B, Laor A, Lupo H, Zivelin A, Lanir N, Seligsohn U. Bleeding predictors in factor XI decient patients. Blood Coagul Fibrinolysis. 1997; 8(8):511-515. 110. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak, and total thrombin generation in a model system. J Thromb Haemost. 2004;2(3):402-413.